secwatch.observer — SEC 8-K summary
======================================

Issuer:     Virpax Pharmaceuticals, Inc. (—)
CIK:        0001708331
Form:       8-K
Filed at:   2023-06-21T23:59:59+00:00
Accession:  0001213900-23-050508
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Virpax (VRPX) names Vinay Shah CFO; Christopher Chipman resigns
---------------------------------------------------------------

- Vinay Shah appointed CFO effective June 20, 2023, succeeding Christopher Chipman who resigned to pursue other opportunities.
- Shah's base salary $312,000; target bonus 30% of base; option to purchase 100,000 shares vesting over 4 years.
- Chipman's separation: $234,000 severance in 4 monthly installments of $58,500; COBRA for 4 months; accelerated option vesting.
- Chipman's resignation not due to any disagreement with the company on operations, policies, or accounting.
- Shah previously served as CFO of Aravive and held finance roles at Pacira Pharmaceuticals; over 30 years of experience.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708331/000121390023050508/0001213900-23-050508-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708331/000121390023050508/ea180640-8k_virpaxpharm.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-050508

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer